A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.
Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer's drug, Leqembi, and other new products gain traction.
Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. last summer.
The drug posted just $10 million in sales last year following its launch.
That compares with a net loss of $68.1 million, or 47 cents per share, for the same period a year ago.
Persons:
Biogen, StreetAccount
Organizations:
U.S, Wall Street, LSEG
Locations:
U.S